Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fizzy-related protein 1 (FZR1), also known as Cdh1, is a crucial co-activator of the Anaphase-Promoting Complex/Cyclosome (APC/C), a multi-subunit E3 ubiquitin ligase [UniProt: Q9UM11]. It functions primarily during late mitosis and the G1 phase of the cell cycle, where it identifies and recruits specific substrates containing a destruction box (D-box) or KEN-box motif for ubiquitination and subsequent proteasomal degradation [PubMed: 25341468]. By regulating the stability of proteins such as Cyclin B1, Securin, and Skp2, FZR1 ensures the orderly exit from mitosis and maintains the G1 state to prevent premature DNA replication [PubMed: 21680707]. In the context of human disease, FZR1 is frequently characterized as a tumor suppressor; its loss or inactivation leads to genomic instability, aneuploidy, and accelerated cell cycle progression in various malignancies [PubMed: 21680707]. Additionally, FZR1 plays non-canonical roles in the nervous system, where it regulates axonal growth and synaptic plasticity, and its dysfunction has been linked to neurodegenerative conditions like Alzheimer's disease [PubMed: 23333473]. Although no FZR1-targeted therapies are currently FDA-approved, small-molecule inhibitors like Apcin have been developed to block the interaction between FZR1 and its substrates, serving as valuable tools for studying cell cycle control and potential anti-cancer strategies [PubMed: 24463511].
Competitive inhibition of the D-box binding site on FZR1 to prevent substrate recruitment to the APC/C complex
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fizzy-related protein 1 (FZR1) (FZR1).